Guerbet SA (EPA:GBT)

Market Cap	282.95M
Revenue (ttm)	851.12M
Net Income (ttm)	16.08M
Shares Out	12.60M
EPS (ttm)	1.28
PE Ratio	17.59
Forward PE	10.50
Dividend	0.50 (2.27%)
Ex-Dividend Date	Jul 1, 2024

Volume	2,638
Average Volume	13,932
Open	22.35
Previous Close	22.45
Day's Range	22.35 - 22.70
52-Week Range	17.42 - 39.35
Beta	0.79
RSI	58.13
Earnings Date	Sep 24, 2025

About Guerbet

Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine; Elucirem, a macrocyclic gadolinium-based contrast agent; and Artirem, a gadoteric acid that acts a...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1926
• Employees: 2,905
• Stock Exchange: Euronext Paris
• Ticker Symbol: GBT

Financial Performance

In 2024, Guerbet's revenue was 851.12 million, an increase of 6.97% compared to the previous year's 795.65 million. Earnings were 16.08 million, a decrease of -32.61%.